| 14.06 12:35 | dpa-AFX: *ALEXION PHARMA SAYS POSITIVE PHASE 3 EXTENSION DATA FOR ULTOMIRIS PRESENTED AT EHA CONGRESS |
| 25.05 05:18 | dpa-AFX: Biotech Stocks Facing FDA Decision In June 2019 |
| 25.05 05:18 | dpa-AFX: Biotech Stocks Facing FDA Decision In June 2019 |
| 25.05 05:17 | dpa-AFX: Biotech Stocks Facing FDA Decision In June 2019 |
| 25.05 05:17 | dpa-AFX: Biotech Stocks Facing FDA Decision In June 2019 |
| 25.04 12:53 | dpa-AFX: Alexion Pharmaceuticals Inc. Q1 adjusted earnings Beat Estimates |
| 25.04 12:53 | dpa-AFX: Alexion Pharmaceuticals Inc. Q1 adjusted earnings Beat Estimates |
| 25.04 12:42 | dpa-AFX: *ALEXION Q1 NON-GAAP EPS $2.39, 42% INCREASE FROM PRIOR YEAR |
| 25.04 12:42 | dpa-AFX: *ALEXION Q1 TOTAL REVENUES $1.14 BLN, UP 23% FROM PRIOR YEAR |
| 25.04 12:35 | dpa-AFX: *ALEXION Q1 GAAP EPS $2.61, UP 135% FROM LAST YEAR |
| 20.03 12:07 | dpa-AFX: *ALEXION AND ZEALAND PHARMA ANNOUNCE COLLABORATION TO DEVELOP PEPTIDE THERAPIES FOR COMPLEMENT-MEDIATED DISEASES |
| 20.03 11:37 | dpa-AFX: *ALEXION TO PROVIDE AFFIBODY WITH UPFRONT PAYMENT OF $25 MLN, WITH POTENTIAL FOR MILESTONES OF UP TO $625 MLN |
| 20.03 11:36 | dpa-AFX: *ALEXION AND AFFIBODY AB ANNOUNCE PARTNERSHIP TO CO-DEVELOP ABY-039 |
| 04.02 13:01 | dpa-AFX: Alexion Pharmaceuticals Q4 18 Earnings Conference Call At 8:00 AM ET |
| 04.02 12:34 | dpa-AFX: *ALEXION PHARMA Q4 NET LOSS $45 MLN OR $0.20/SHR VS. NET INCOME $30.0 MLN OR $0.13/SHR LAST YEAR |
| 04.02 12:34 | dpa-AFX: *ALEXION PHARMA Q4 TOTAL REVENUES UP 24% TO $1.128 BLN |
| 04.02 12:33 | dpa-AFX: *ALEXION PHARMA Q4 NON-GAAP EPS $2.14, CONSENSUS $1.82 |
| 31.01 12:33 | dpa-AFX: *ALEXION TO ACQUIRE CAELUM BASED ON PHASE 2 DATA |
| 31.01 12:33 | dpa-AFX: *CAELUM TO RECEIVE UP TO $60 MLN FOR EQUITY INVESTMENT AND OPTION FEE |
| 31.01 12:32 | dpa-AFX: *FORTRESS-FOUNDED CAELUM BIOSCIENCES TO RECEIVE $60 MLN IN STRATEGIC EQUITY INVESTMENT AND OPTION FEE |
|
|
